| Detected | Trial | Change |
|---|---|---|
| 2026-06-09 | NCT07422610 Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies… |
Trial sites expanded: 2 -> 5 locations |
| 2026-06-03 | NCT07357727 A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) |
Trial sites expanded: 6 -> 9 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT06401356 | An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | Hematologic Malignancy | Recruiting |
| NCT07357727 | A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF) | Primary Myelofibrosis (PMF) | Recruiting |
| Phase 1 | |||
| NCT07422610 | Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies… | Advanced Malignancies and Hepatic Impairment | Recruiting |
| NCT07340138 | Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis | Primary Myelofibrosis (PMF) | Recruiting |
| NCT07340190 | A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the… | Advanced Malignancies | Not Yet Recruiting |